News und Analysen
EQS-News: Eckert & Ziegler with Strong Sales Growth in the First Quarter of 2023
EQS-News: Eckert & Ziegler with Strong Sales Growth in the First Quarter of 2023
EQS-News: Eckert & Ziegler: Recognized Australian Endocrine & Hypertension Center Joins International Groups with a Clinical Trial of PentixaPharm’s Primary Aldosteronism Lead Candidate
EQS-News: Eckert & Ziegler: Recognized Australian Endocrine & Hypertension Center Joins International Groups with a Clinical Trial of PentixaPharm’s Primary Aldosteronism Lead Candidate
EQS-News: MediClin AG: Encouraging development of Group sales in the first quarter of 2023
EQS-News: MediClin AG: Encouraging development of Group sales in the first quarter of 2023
EQS-News: MediClin AG: Mercurius Health acquires Robert Janker Klinik in Bonn, Germany, previously owned by MEDICLIN
EQS-News: MediClin AG: Mercurius Health acquires Robert Janker Klinik in Bonn, Germany, previously owned by MEDICLIN
EQS-News: Development of Vita 34 AG in 2022 stressed by weakened consumption power of consumers along with one-off effects
EQS-News: Development of Vita 34 AG in 2022 stressed by weakened consumption power of consumers along with one-off effects
EQS-Adhoc: Vita 34 AG publishes outlook for the 2023 financial year
EQS-Adhoc: Vita 34 AG publishes outlook for the 2023 financial year
EQS-Adhoc: Eckert & Ziegler Publishes Preliminary Figures for Q1/2023 with Double-digit Sales Growth, Earnings Decline and Confirmation of 2023 Full-Year Guidance
EQS-Adhoc: Eckert & Ziegler Publishes Preliminary Figures for Q1/2023 with Double-digit Sales Growth, Earnings Decline and Confirmation of 2023 Full-Year Guidance
EQS-Adhoc: M1 Kliniken AG decides to start share buyback
EQS-Adhoc: M1 Kliniken AG decides to start share buyback
EQS-News: Eckert & Ziegler Receives Manufacturing Authorization for GMP-grade Lutetium-177
EQS-News: Eckert & Ziegler Receives Manufacturing Authorization for GMP-grade Lutetium-177
EQS-News: M1 Kliniken AG publishes preliminary figures for financial year 2022
EQS-News: M1 Kliniken AG publishes preliminary figures for financial year 2022
EQS-News: Eckert & Ziegler Receives Environmental Approval for Jintan Radioisotope Site
EQS-News: Eckert & Ziegler Receives Environmental Approval for Jintan Radioisotope Site
EQS-Adhoc: 2022 annual result of Vita 34 AG significantly influenced by impairment of goodwill
EQS-Adhoc: 2022 annual result of Vita 34 AG significantly influenced by impairment of goodwill
EQS-News: Eckert & Ziegler to Supply POINT Biopharma with Actinium-225
EQS-News: Eckert & Ziegler to Supply POINT Biopharma with Actinium-225
EQS-News: MediClin AG: Group sales and Group operating result above previous year − cautious outlook for 2023
EQS-News: MediClin AG: Group sales and Group operating result above previous year − cautious outlook for 2023
EQS-News: Eckert & Ziegler: Successful fiscal year 2022
EQS-News: Eckert & Ziegler: Successful fiscal year 2022
EQS-News: Eckert & Ziegler Plans Change of Legal Form to European Stock Corporation (SE)
EQS-News: Eckert & Ziegler Plans Change of Legal Form to European Stock Corporation (SE)
EQS-News: Eckert & Ziegler with Unchanged Dividend Proposal
EQS-News: Eckert & Ziegler with Unchanged Dividend Proposal
EQS-News: Eckert & Ziegler Submits Drug Master File for Lu-177 n.c.a.
EQS-News: Eckert & Ziegler Submits Drug Master File for Lu-177 n.c.a.
EQS-News: MediClin AG: Disclosure of the preliminary figures of the 2022 financial year
EQS-News: MediClin AG: Disclosure of the preliminary figures of the 2022 financial year
EQS-News: Lausanne University Hospital Investigates Use of PENTIXAFOR in Cardio-Vascular Setting
EQS-News: Lausanne University Hospital Investigates Use of PENTIXAFOR in Cardio-Vascular Setting
EQS-Adhoc: Eckert & Ziegler Exceeds Forecast for the 2022 Financial Year According to Preliminary Figures
EQS-Adhoc: Eckert & Ziegler Exceeds Forecast for the 2022 Financial Year According to Preliminary Figures
EQS-News: Change in the Supervisory Board of Eckert & Ziegler AG
EQS-News: Change in the Supervisory Board of Eckert & Ziegler AG
EQS-Adhoc: Changes in the Management Board of Eckert & Ziegler
EQS-Adhoc: Changes in the Management Board of Eckert & Ziegler
EQS-Adhoc: Eckert & Ziegler Receives Green Light for Phase III Study with PENTIXAFOR
EQS-Adhoc: Eckert & Ziegler Receives Green Light for Phase III Study with PENTIXAFOR
EQS-News: Expansion of the Management Board of M1 Kliniken AG
EQS-News: Expansion of the Management Board of M1 Kliniken AG